Please login to the form below

Not currently logged in
Email:
Password:

enzastaurin

This page shows the latest enzastaurin news and features for those working in and with pharma, biotech and healthcare.

Lilly/Boehringer's empagliflozin faces US approval delay

Lilly/Boehringer's empagliflozin faces US approval delay

last year it suffered late-stage setbacks with antidepressant edivoxetine, enzastaurin for lymphoma and tabalumab for rheumatoid arthritis.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics